Philippe Atlan1, Mohamed Amine Bayar2,3, Emilie Lanoy2,3, Benjamin Besse4, David Planchard4, Jordy Ramon4, Bruno Raynard5, Sami Antoun6. 1. Département Interdisciplinaire de Soins de Support, Gustave-Roussy, Université Paris-Saclay, 114 rue Edouard Vaillant, F-94805, Villejuif, France. Philippe.ATLAN@gustaveroussy.fr. 2. Service de Biostatistique et d'Epidémiologie, Gustave-Roussy, Université Paris-Saclay, F-94805, Villejuif, France. 3. Université Paris-Saclay, Univ. Paris-Sud, UVSQ, CESP, INSERM, F-94805, Villejuif, France. 4. Département d'Oncologie Médicale, Gustave-Roussy, Université Paris-Saclay, F-94805, Villejuif, France. 5. Département Interdisciplinaire de Soins de Support, Gustave-Roussy, Université Paris-Saclay, 114 rue Edouard Vaillant, F-94805, Villejuif, France. 6. Département Ambulatoire, Gustave-Roussy, Université Paris-Saclay, F-94805, Villejuif, France.
Abstract
PURPOSE: Advanced non-small cell lung cancer (NSCLC) is associated with weight loss which may reflect skeletal muscle mass (SMM) and/or total adipose tissue (TAT) depletion. This study aimed to describe changes in body composition (BC) parameters and to identify the factors unrelated to the tumor which modulate them. METHODS: SMM, TAT, and the proportion of SMM to SMM + TAT were assessed with computed tomography. Estimates of each BC parameter at follow-up initiation and across time were derived from a mixed linear model of repeated measurements with a random intercept and a random slope. The same models were used to assess the independent effect of gender, age, body mass index (BMI), and initial values on changes in each BC parameter. RESULTS: Sixty-four patients with stage III or IV NSCLC were reviewed. The mean ± SD decreases in body weight and SMM were respectively 59 ± 3 g/week (P < 0.03) and 7 mm2/m2/week (P = 0.0003). During follow-up, no changes were identified in TAT nor in muscle density or in the proportion of SMM to SMM + TAT, estimated at 37 ± 2% at baseline. SMM loss was influenced by initial BMI (P < 0.0001) and SMM values (P = 0.0002): the higher the initial BMI or SMM values, the greater the loss observed. Weight loss was greater when the initial weight was heavier (P < 0.0001). CONCLUSION: Our results demonstrate that SMM wasting in NSCLC is lower when initial SMM and BMI values are low. These exploratory findings after our attempt to better understand the intrinsic factors associated with muscle mass depletion need to be confirmed in larger studies.
PURPOSE: Advanced non-small cell lung cancer (NSCLC) is associated with weight loss which may reflect skeletal muscle mass (SMM) and/or total adipose tissue (TAT) depletion. This study aimed to describe changes in body composition (BC) parameters and to identify the factors unrelated to the tumor which modulate them. METHODS: SMM, TAT, and the proportion of SMM to SMM + TAT were assessed with computed tomography. Estimates of each BC parameter at follow-up initiation and across time were derived from a mixed linear model of repeated measurements with a random intercept and a random slope. The same models were used to assess the independent effect of gender, age, body mass index (BMI), and initial values on changes in each BC parameter. RESULTS: Sixty-four patients with stage III or IV NSCLC were reviewed. The mean ± SD decreases in body weight and SMM were respectively 59 ± 3 g/week (P < 0.03) and 7 mm2/m2/week (P = 0.0003). During follow-up, no changes were identified in TAT nor in muscle density or in the proportion of SMM to SMM + TAT, estimated at 37 ± 2% at baseline. SMM loss was influenced by initial BMI (P < 0.0001) and SMM values (P = 0.0002): the higher the initial BMI or SMM values, the greater the loss observed. Weight loss was greater when the initial weight was heavier (P < 0.0001). CONCLUSION: Our results demonstrate that SMM wasting in NSCLC is lower when initial SMM and BMI values are low. These exploratory findings after our attempt to better understand the intrinsic factors associated with muscle mass depletion need to be confirmed in larger studies.
Entities:
Keywords:
Adipose tissue; Cachexia; Sarcopenia; Skeletal muscle mass; Weight loss
Authors: Verena K Haas; Michael R Kohn; Simon D Clarke; Jane R Allen; Sloane Madden; Manfred J Müller; Kevin J Gaskin Journal: Am J Clin Nutr Date: 2009-02-11 Impact factor: 7.045
Authors: Sami Antoun; Emilie Lanoy; Roberto Iacovelli; Laurence Albiges-Sauvin; Yohann Loriot; Mansouriah Merad-Taoufik; Karim Fizazi; Mario di Palma; Vickie E Baracos; Bernard Escudier Journal: Cancer Date: 2013-06-25 Impact factor: 6.860
Authors: Katie M Di Sebastiano; Lin Yang; Kevin Zbuk; Raimond K Wong; Tom Chow; David Koff; Gerald R Moran; Marina Mourtzakis Journal: Br J Nutr Date: 2012-07-04 Impact factor: 3.718
Authors: Relin Yang; Michael C Cheung; Felipe E Pedroso; Margaret M Byrne; Leonidas G Koniaris; Teresa A Zimmers Journal: J Surg Res Date: 2011-05-23 Impact factor: 2.192
Authors: Sophie Cousin; A Hollebecque; S Koscielny; O Mir; A Varga; V E Baracos; J C Soria; S Antoun Journal: Invest New Drugs Date: 2013-12-17 Impact factor: 3.850
Authors: Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray Journal: Int J Cancer Date: 2014-10-09 Impact factor: 7.396
Authors: Suman K Das; Sandra Eder; Silvia Schauer; Clemens Diwoky; Hannes Temmel; Barbara Guertl; Gregor Gorkiewicz; Kuppusamy P Tamilarasan; Pooja Kumari; Michael Trauner; Robert Zimmermann; Paul Vesely; Guenter Haemmerle; Rudolf Zechner; Gerald Hoefler Journal: Science Date: 2011-06-16 Impact factor: 47.728
Authors: Jeroen W G Derksen; Sophie A Kurk; Marieke J Oskam; Petra H M Peeters; Cornelis J A Punt; Miriam Koopman; Anne M May Journal: JNCI Cancer Spectr Date: 2019-04-25
Authors: Sophie A Kurk; Petra H M Peeters; Bram Dorresteijn; Pim A de Jong; Marion Jourdan; Geert-Jan M Creemers; Frans L G Erdkamp; Felix E de Jongh; Peter A M Kint; Boelo J Poppema; Sandra A Radema; Lieke H J Simkens; Bea C Tanis; Manuel L R Tjin-A-Ton; Ankie Van Der Velden; Cornelis J A Punt; Miriam Koopman; Anne M May Journal: Cancer Med Date: 2019-12-18 Impact factor: 4.452